Search results
Results from the WOW.Com Content Network
Mosunetuzumab, sold under the brand name Lunsumio, is a monoclonal antibody used for the treatment of follicular lymphoma. [2] [3] [5] It bispecifically binds CD20 and CD3 to engage T-cells. [2] [3] It was developed by Genentech. [6] The most common adverse reactions (≥20%) include cytokine release syndrome, fatigue, rash, pyrexia, and headache.
Talquetamab, sold under the brand name Talvey, is a humanized monoclonal antibody used for the treatment of multiple myeloma. It is a bispecific GPRC5D-directed CD3 T-cell engager.
Obinutuzumab has two black box warnings: hepatitis B reactivation and progressive multifocal leukoencephalopathy. [7] [5]In the clinical trial of obinutuzumab in combination with chlorambucil, participants experienced infusion reactions (69%; 21% grade 3/4), neutropenia (40%; 34% grade 3/4), thrombocytopenia (15%; 11% grade 3/4), anemia (12%), and pyrexia and cough (10% each).
Elon Musk's Department of Government Efficiency has sparked concerns within the intelligence community after it posted information about an agency that oversees U.S. intelligence satellites to its ...
Trump asked for review of plan. The congestion pricing plan, which launched on Jan. 5, charged passenger vehicles $9 to access Manhattan below 60th Street during peak hours as part of an effort to ...
Mark and his siblings grew up in Dorchester, a neighborhood in Boston. Their mother Alma Wahlberg worked as a bank clerk and nurse’s aide while they were kids, and their father Donald Wahlberg ...
The US Food and Drug Administration (FDA) granted the application for moxetumomab pasudotox fast track, priority review, and orphan drug designations. [4] [17] The FDA granted the approval of a Biologics License Application for Lumoxiti to AstraZeneca Pharmaceuticals. [4] This was subsequently transferred to Innate Pharma in March 2020. [18]
Brian Cox defended Kevin Spacey in a new interview with U.K. publication The i Paper, calling the Oscar winner “an old friend of mine” and asking the public: “How dare you cancel anybody?”